Independent pricing breakdown · May 2026
Quick answer
Semaglutide costs $968–$1,349 per month for brand-name versions (Ozempic, Wegovy, Rybelsus) at retail pharmacies in 2026. With insurance, most patients pay $0–$50 per month. Direct manufacturer cash-pay programs start at $349 per month for Wegovy. Compounded semaglutide through telehealth providers is the cheapest legal pathway, starting at $99 per month.
Sorted by source. Average list pricing for a standard 30-day supply at typical dose.
| Source | Monthly cost | Note |
|---|---|---|
| Wegovy retail | $1,349/month | Highest brand-name price; weight-loss FDA approval |
| Ozempic retail | $968/month | Type 2 diabetes FDA approval |
| Rybelsus (oral) retail | $1,049/month | Oral semaglutide tablet form |
| Wegovy direct cash-pay | $349/month | Novo Nordisk NovoCare program |
| Compounded semaglutide (telehealth) | $99–$275/month | Varies by provider and plan length |
| Compounded semaglutide first-order | From $99/month | New-patient discount; 3- and 6-month plans |
Semaglutide is sold under three brand names in the US, each at different price points and FDA indications. Wegovy at $1,349 per month is the most expensive — approved for chronic weight management. Ozempic at $968 per month is approved for type 2 diabetes. Rybelsus at $1,049 per month is the oral tablet form, also approved for type 2 diabetes.
All three contain the same molecule. The price differences reflect dose, indication, and formulation rather than ingredient.
Compounded semaglutide pricing in 2026 ranges from $99 per month at the cheapest legitimate telehealth providers up to about $275 per month at higher-touch programs. The variation reflects provider service level: longer-plan commitments generally produce lower effective monthly rates.
First-order pricing on compounded semaglutide can drop the effective month-one cost to $99 across multiple programs. Three- and six-month plans lock in lower per-month rates than monthly subscriptions.
Brand-name semaglutide pricing covers Novo Nordisk's R&D recovery, manufacturing infrastructure, marketing, and shareholder return on a patent-protected single-source product. Compounded semaglutide is prepared in 503A licensed pharmacies from FDA-regulated active ingredients, with no R&D recovery embedded in the price.
Compounded medications are not FDA-approved as finished drugs and not directly equivalent to brand-name products in regulatory terms. They are legal when prescribed by a licensed provider for a specific patient, prepared in a licensed compounding pharmacy.
Top-rated telehealth providers offering compounded equivalents to brand-name medications. Sorted by editorial rating.
Comprehensive GLP-1 programs with board-certified physicians and lab monitoring
Excellent
Highest-converting GLP-1 provider — $16 EPC, personalized consultations, tailored prescriptions
Excellent
Fastest-growing GLP-1 provider — oral, sublingual, and injectable options with Affirm financing
Excellent
150K+ members with 5 medication forms — injections, oral drops, lozenges, tablets, and pills
Very Good
Compounded semaglutide via licensed telehealth providers at $99 per month is the cheapest. Among brand-name options, Novo Nordisk's direct cash-pay Wegovy program at $349 per month is the cheapest path.
Compounded semaglutide is legal and clinically used when prepared in a 503A licensed pharmacy under provider supervision. It is not FDA-approved as a finished drug. Quality varies by provider — only use programs whose pharmacy partner is LegitScript-certified.
Some patients access semaglutide internationally at lower prices, but the FDA does not authorize personal-import of compounded or non-approved formulations. The legal pathways within the US are insurance, manufacturer cash-pay programs, and licensed telehealth compounded options.